Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, Cohen M, Kleiman NS, Langer A, Aylward PE, Col JJ, Reist C, Ferguson JJ, Califf RM; SYNERGY Trial Investigators. Mahaffey KW, et al. Among authors: reist c. J Gen Intern Med. 2008 Mar;23(3):310-6. doi: 10.1007/s11606-007-0498-4. Epub 2008 Jan 15. J Gen Intern Med. 2008. PMID: 18196350 Free PMC article. Clinical Trial.
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ; SYNERGY Library. Petersen JL, et al. Among authors: reist cj. Am Heart J. 2004 Aug;148(2):269-76. doi: 10.1016/j.ahj.2004.03.022. Am Heart J. 2004. PMID: 15308996 Clinical Trial.
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ 3rd, Califf RM; SYNERGY Trial Investigators. Mahaffey KW, et al. JAMA. 2005 Nov 23;294(20):2594-600. doi: 10.1001/jama.294.20.2594. JAMA. 2005. PMID: 16304073 Clinical Trial.
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, Roe MT, Newby LK, Harrington RA, Ferguson JJ, Califf RM, Mahaffey KW. Linefsky JP, et al. Am J Cardiol. 2009 Nov 15;104(10):1330-5. doi: 10.1016/j.amjcard.2009.06.056. Epub 2009 Sep 25. Am J Cardiol. 2009. PMID: 19892046 Clinical Trial.
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.
Becker RC, Mahaffey KW, Yang H, Marian AJ, Furman MI, Michael Lincoff A, Hazen SL, Petersen JL, Reist CJ, Kleiman NS; SYNERGY Investigators. Becker RC, et al. Among authors: reist cj. J Thromb Thrombolysis. 2011 Feb;31(2):146-53. doi: 10.1007/s11239-010-0532-y. J Thromb Thrombolysis. 2011. PMID: 21086021 Clinical Trial.
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RM. Blazing MA, et al. Among authors: reist c. Am Heart J. 2014 Aug;168(2):205-12.e1. doi: 10.1016/j.ahj.2014.05.004. Epub 2014 May 15. Am Heart J. 2014. PMID: 25066560 Free article.
Determinants of plasma vitamin D levels in patients with acute coronary syndromes.
Rodriguez G, Starr AZ, Czernuszewicz GZ, Manhas A, Alhariri A, Willerson JT, Reist CJ, Pieper K, Mahaffey KW, Marian AJ, Kleiman NS. Rodriguez G, et al. Eur J Clin Invest. 2011 Dec;41(12):1299-309. doi: 10.1111/j.1365-2362.2011.02540.x. Epub 2011 May 25. Eur J Clin Invest. 2011. PMID: 21615392
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
Berger JS, Abramson BL, Lopes RD, Heizer G, Rockhold FW, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Millegård M, Blomster J, Reist C, Hiatt WR, Patel MR, Mahaffey KW. Berger JS, et al. Among authors: reist c. Vasc Med. 2018 Dec;23(6):523-530. doi: 10.1177/1358863X18775594. Epub 2018 Jul 11. Vasc Med. 2018. PMID: 29992857 Clinical Trial.
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.
van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, Roe MT, Ezekowitz JA, Moliterno DJ, Neumann FJ, Reist C, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Granger CB, Theroux P; APEX AMI Investigators. van Diepen S, et al. Among authors: reist c. Int J Cardiol. 2013 Oct 3;168(3):2127-33. doi: 10.1016/j.ijcard.2013.01.004. Epub 2013 Feb 8. Int J Cardiol. 2013. PMID: 23394896 Clinical Trial.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Cannon CP, et al. Among authors: reist c. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3. N Engl J Med. 2015. PMID: 26039521 Free article. Clinical Trial.
129 results